CION Ameerpet
Pancreatic Cancer · Treatment & Modalities · Reviewed by CION Oncologists
Immunotherapy for pancreatic cancer — who it actually helps
Immunotherapy has changed the outlook in several cancers. In pancreatic cancer it helps a small, precisely defined group — tumours that are MSI-high or mismatch repair deficient — and does not help the large majority. This page explains who that group is, how the test is done, and what it means if you are not in it.
- Only a biomarker-defined subgroup benefits — checkpoint immunotherapy works where the tumour is MSI-high or mismatch repair deficient.
- A test decides it, not a guess — MMR and MSI status is read from tumour tissue, and NCCN guidance advises checking it.
- It does not replace chemotherapy — for mismatch repair proficient tumours, systemic chemotherapy remains the backbone.
- A positive result changes more than treatment — it can point to Lynch syndrome, and to testing for your close relatives.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What Immunotherapy Does, and Where Pancreatic Cancer Fits
People searching for immunotherapy pancreatic cancer usually want to know one thing: is there a treatment here that is not chemotherapy? The honest answer comes in two halves, and both halves matter. For the large majority of pancreatic adenocarcinomas, immune checkpoint therapy given on its own does not work. For a small, precisely defined subgroup, it can work very well — and that subgroup is identified by a laboratory test, not by how the tumour looks on a scan or how you feel.
Checkpoint inhibitors do not attack a tumour directly. They release a brake that tumours use to switch off the immune cells already around them. For that to help, the immune system has to be able to recognise the tumour as abnormal in the first place. Most pancreatic tumours are difficult on both counts. They sit inside a dense fibrous stroma that physically limits immune traffic, they recruit cells that actively suppress an immune response, and they usually carry a relatively low mutation load, so there is little for a T cell to recognise. Oncologists call this an immunologically cold tumour, and it is why checkpoint blockade alone has repeatedly disappointed in unselected pancreatic cancer.
The exception is a tumour whose DNA mismatch repair machinery is broken. When one of those repair proteins is missing, errors pile up across the genome, especially in short repeated stretches of DNA called microsatellites — hence the two terms you will see on a report, mismatch repair deficient (dMMR) and microsatellite instability high (MSI-high). A tumour like that produces a great many abnormal proteins, which makes it visible to the immune system in a way an ordinary pancreatic tumour is not. MSI-high pancreatic cancer is rare, but it is not theoretical, and where it is present the benefit from checkpoint blockade can be substantial and durable. It is also a finding that can point towards Lynch syndrome and inherited pancreatic cancer risk, which changes the conversation for your relatives as well as for you.
Did you know? Checking a pancreatic tumour's mismatch repair status is not an optional extra. NCCN guidance on pancreatic adenocarcinoma recommends germline testing for everyone with a confirmed diagnosis, and tumour molecular profiling that includes MMR or MSI status for patients with locally advanced or metastatic disease who are being considered for systemic therapy. MSI-high status was also the basis of the first treatment approval in modern oncology granted for a biomarker rather than for the organ the cancer started in — the result carries the same meaning whether the tumour began in the pancreas, the bowel or the lining of the womb. That is why a single line in a pathology report can matter more here than almost anything else on it.
Reading your own paperwork
What Your Pathology and Molecular Report Is Actually Saying
These terms appear on Indian and international reports in slightly different formats. Here is what each one means for the immunotherapy question.
dMMR
Mismatch repair deficient
Immunohistochemistry shows that one or more of the mismatch repair proteins is absent from the tumour cells. This is the finding that opens the checkpoint immunotherapy conversation.
MSI-high
Microsatellite instability high
A different way of measuring the same underlying fault, by looking at repeated DNA sequences directly. dMMR and MSI-high usually travel together and are treated as equivalent.
pMMR / MSS
Proficient, or microsatellite stable
The far more common result. Checkpoint immunotherapy on its own is not expected to help, and chemotherapy for advanced pancreatic cancer remains the backbone of treatment.
Germline or somatic
Where the fault came from
A repair fault can be inherited, as in Lynch syndrome, or acquired by the tumour alone. Genetic counselling separates the two, and only the inherited kind has implications for your family.
TMB
Tumour mutational burden
Often reported alongside. A high burden frequently accompanies a mismatch repair fault and is one of the signals a tumour board weighs when the MMR result is borderline or unclear.
Sample adequacy
Whether there was enough tumour to test
A small aspirate sometimes yields too few tumour cells for reliable testing. Where a fresh sample is needed, an endoscopic ultrasound-guided biopsy is arranged with our specialist endoscopy partners.
What the result changes
Two Different Conversations, Depending on the Result
The same scan, the same stage and the same symptoms can lead to two quite different treatment discussions once the mismatch repair result is known. This is what actually shifts.
| What the report says | What it changes about treatment | What it changes for your family |
|---|---|---|
| dMMR or MSI-high | Immune checkpoint inhibitor therapy becomes a genuine option, and is discussed alongside chemotherapy rather than instead of it. Sequencing depends on how much disease there is and how well you are. | Genetic counselling is offered, because an inherited repair fault may be behind it and close relatives may benefit from testing. |
| pMMR or microsatellite stable | Checkpoint immunotherapy alone is not offered, because the evidence does not support it here. Combination chemotherapy, and radiation or chemoradiation where appropriate, carry the plan. | Nothing on its own, though germline testing is still recommended for everyone with pancreatic adenocarcinoma for other reasons. |
| Not tested, or the result is missing | The question stays open, which is the least useful position to be in. Existing paraffin blocks can usually be sent for testing without another procedure. | Also stays open. Family testing decisions are easier once the tumour result is known. |
If you have a pathology report and cannot tell whether MMR status was ever checked, bring it in and we will read it with you. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
One Line in a Pathology Report Can Change the Plan
Finding out whether mismatch repair status was ever checked takes one consultation, not another procedure.
What actually happens
How We Establish Whether This Applies to You
-
Read the reports you already have
Mismatch repair status is often already sitting in a pathology report, written as four protein names rather than as a headline. The first job is to find out whether it was ever done.
In-house at CION -
Send the existing block for testing
If the tissue is stored and adequate, MMR immunohistochemistry and MSI testing can usually be added to the original sample. No second procedure is needed for most people.
Ordered and reported in-house at CION -
Obtain fresh tissue only if we must
Where the stored sample is too small, a repeat endoscopic ultrasound-guided biopsy is arranged. This is done by our partner endoscopy service, at their unit, and may be billed there.
Coordinated with specialist endoscopy partners -
Offer genetic counselling if the result is positive
A dMMR tumour raises the question of an inherited repair fault. Counselling and germline testing separate an inherited cause from one the tumour acquired on its own.
In-house at CION -
Take the case to the tumour board
Pathology, imaging, fitness and the molecular result are discussed together, so the plan reflects what medical oncology, radiation oncology and the surgical partners each think is achievable.
Tumour board at CION -
Set the plan, and say what would change it
Checkpoint inhibitor therapy where the biomarker supports it, chemotherapy where it does not, with the reassessment points agreed in advance. Pancreatic cancer treatment in Hyderabad sets out the full range of options.
Systemic therapy in-house at CION
Plainly stated
What CION Delivers, and What Is Coordinated
Your first consultation is free and lasts 45 minutes. It is a proper review of your reports, not a booking appointment, and it is the fastest way to find out whether the immunotherapy question has already been answered somewhere in your file.
Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: medical oncology, including immune checkpoint inhibitor therapy where the tumour is mismatch repair deficient, and chemotherapy before surgery, after surgery and for advanced disease; the ordering and reporting of MMR and MSI testing on existing biopsy material, pancreatic-protocol CT, MRI/MRCP, CA 19-9 and bloods; genetic counselling; radiation, chemoradiation and SBRT; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up. Immunotherapy is given as a day-care infusion under specialist supervision, with monitoring for the immune-related effects that this class can cause.
Coordinated with specialist HPB, gastroenterology and endoscopy partner centres, and may be billed there: endoscopic ultrasound with biopsy, including a repeat biopsy for molecular testing; all pancreatic surgery; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we sit in on the decisions, and we tell you in advance where each one happens and who invoices you. We do not describe them as our own theatre or endoscopy lists, because they are not.
If you are earlier in the process than this page assumes, the complete guide to pancreatic cancer covers diagnosis, staging and the wider treatment picture before the molecular detail becomes relevant.
Bring the pathology report and any molecular or genetic report you have. Those documents settle the immunotherapy question faster than any consultation without them. Book a free consultation or call 1800 202 8726.
Take the next step
Get a Straight Answer on Immunotherapy
We will tell you whether this applies to you, and what to do next if it does not. We walk this journey with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy for pancreatic cancer — your questions answered
Does immunotherapy work for pancreatic cancer?
For most people with pancreatic cancer, immune checkpoint therapy given on its own does not work, and it is better to hear that plainly than to spend months chasing it. Pancreatic tumours are usually immunologically cold: they sit in dense scar-like tissue that limits immune traffic, they recruit cells that suppress the immune response, and they carry relatively few mutations for the immune system to recognise. There is one clear exception. Where the tumour is mismatch repair deficient or microsatellite instability high, checkpoint blockade can produce a real and sometimes lasting response. That group is small, but the only way to know whether you are in it is a laboratory test on the tumour tissue, so the practical question is not whether immunotherapy works in general but whether your own tumour has been tested.
What do MSI-high and dMMR actually mean?
Both terms describe the same underlying fault, measured in two different ways. Cells carry a repair system that proofreads DNA as it is copied. When one of the proteins in that system is missing, the tumour is called mismatch repair deficient, or dMMR, and this is usually detected by staining the tissue for those proteins. The uncorrected errors build up fastest in short repeated stretches of DNA called microsatellites, so a test that looks at those stretches directly reports the tumour as microsatellite instability high, or MSI-high. In practice the two results are treated as equivalent. What matters clinically is that such a tumour makes a large number of abnormal proteins, which is exactly what an immune checkpoint inhibitor needs the immune system to be able to see.
How do I find out whether my tumour is MSI-high or dMMR?
Start by looking at the pathology report you already have. Mismatch repair testing is often reported as a list of protein names with the words present or lost beside each one, rather than as a clear headline, so it is easy to miss. If it was never done, the stored paraffin block from your original biopsy or operation can usually be sent for testing without any new procedure, which is the route most people take. Only where the stored sample is too small or has too few tumour cells does a fresh endoscopic ultrasound-guided biopsy become necessary, and that is arranged with our specialist endoscopy partners. Bring every report you have to the consultation, including reports from other hospitals, because the answer is often already on paper.
My report says mismatch repair proficient. What are my options?
A proficient or microsatellite stable result is the common one, and it means checkpoint immunotherapy on its own is not the right treatment for you. That is disappointing to read, but it is useful information, because it stops time being lost on a treatment that will not help. Systemic chemotherapy remains the backbone of treatment, chosen according to how much disease there is, how well you are and what your organs will tolerate, and radiation or chemoradiation is added in selected situations. Surgery is considered separately, and depends on the tumour's relationship to the blood vessels behind the pancreas. Genetic testing is still recommended, because inherited changes other than repair faults can influence which class of drug is chosen and can matter for your relatives.
If my tumour is dMMR, does that mean my family is at risk?
Not automatically, but it is a question worth answering properly rather than assuming either way. A repair fault can be inherited, in which case it is part of Lynch syndrome and close relatives may carry the same change, or it can be acquired by the tumour alone during a person's lifetime, in which case there is no inherited risk to pass on. Only germline testing, on a blood or saliva sample rather than the tumour, can tell those two apart. Genetic counselling comes first, so you understand what a result would mean before the test is done, and it is available in-house at CION. Where an inherited cause is confirmed, relatives can be offered testing and, if they carry the change, an appropriate surveillance plan for the cancers linked to it.
What does CION do about this, and what happens at the first visit?
The first consultation is free and lasts 45 minutes. We read your pathology, imaging and any molecular reports with you, establish whether mismatch repair status has already been checked, and arrange testing on the stored tissue if it has not. Where the result supports it, immune checkpoint inhibitor therapy is given in-house at CION as a day-care infusion, with monitoring for the immune-related effects this class can cause; where it does not, we set out the chemotherapy and radiation plan honestly instead. Genetic counselling, imaging, CA 19-9 and bloods, nutrition and enzyme support and supportive care are all in-house across our 35+ centres. Endoscopic biopsy, all pancreatic surgery, ERCP and stenting, PET-CT and DOTATATE PET are coordinated with specialist partner centres and may be billed there. You leave with a written plan and a named point of contact.
Medical disclaimer: This page explains where immune checkpoint therapy fits in pancreatic cancer and what mismatch repair and microsatellite instability testing mean, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma. It is general information about a treatment class, not a recommendation for any individual and not a substitute for a consultation; no molecule or regimen is named here, and whether any treatment suits you depends on your pathology, imaging and general health. Medical oncology including checkpoint inhibitor administration, chemotherapy, radiation, chemoradiation and SBRT, the ordering and reporting of MMR and MSI testing, pancreatic-protocol CT, MRI/MRCP, CA 19-9 and bloods, genetic counselling, nutrition and pancreatic enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION. Endoscopic ultrasound and biopsy, all pancreatic surgery, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.